QYUNS-B(02509): The Phase III clinical trial of QX002N for the treatment of ankylosing spondylitis has achieved its primary endpoint.

QYUNS-B (02509) has announced that the Phase III clinical trial of QX002N injection, developed independently by the company, for the treatment of ankylosing spondylitis (AS) has achieved its primary endpoint. The data shows that QX002N has demonstrated excellent efficacy, as well as good safety and tolerability, in patients with moderate to severe active ankylosing spondylitis. This trial was a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Zeng Xiaofeng from Peking Union Medical College Hospital to evaluate the efficacy and safety of QX002N injection in patients with active ankylosing spondylitis. The study has completed its initial analysis, with a total of 641 participants with moderate to severe active ankylosing spondylitis included, with 322 in the QX002N group and 319 in the placebo group.